title: [Effects of preoperative systemic chemotherapy with respect to expressions of hormone receptors and HER2 / neu].
abstract: METHODS
  Between August 2003 and January 2008, 35 patients with primary breast cancer received preoperative systemic chemotherapy(PSC).
  
  
  METHODS
  The subjects were divided into 4 groups based on the expressions of ER, PgR, and HER2: luminal A and B, HER2, and basal-like groups. FEC75 followed by docetaxel was administered preoperatively. However, a regimen with trastuzumab was employed after 2006.
  
  
  RESULTS
  The subjects consisted of 1 male and 34 females, with a mean age of 56.0 years. In 65.7% of these, axillar lymph node metastasis was detected before surgery: 13 patients in the luminal A, 4 in the luminal B, 13 in the HER2, and 5 in the basal-like groups. A clinical complete response(cCR)was achieved in 25.7% of the patients, and a partial response in 62.9%; the response rate was 88.6%. Pathologically, the grade was evaluated as 3 in 14.3% of the patients and 2 in 48.6%. In the basal-like and HER2 groups, the cCR and pCR rates were higher than those in the luminal groups. Combination therapy with trastuzumab was not effective in the HER2 or luminal B group.
  
  
  CONCLUSIONS
  This simple classification method may be useful for predicting the effects of PSC.
authors.affiliation: Dept. of Surgery, Fukui Prefectural Hospital, Japan.
authors.forename: Kouji
authors.initials: K
authors.lastname: Ohta
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Ito
authors.forename: Tamon
authors.initials: T
authors.lastname: Miyanaga
authors.forename: Kenji
authors.initials: K
authors.lastname: Dohden
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hattori
authors.forename: Osamu
authors.initials: O
authors.lastname: Hosokawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takeda
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kaizaki
authors.forename: Tomoe
authors.initials: T
authors.lastname: Kiya
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab